Immunohistochemistry or IHC
Prognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis
Annals of Surgical Oncology 2026 August 25 [Link] Jan Philipp Ramspott, Anna Kolmhofer, Ibrahim Büdeyri, Michael Weitzendorfer, Stephan Regenbogen, Lukas Schabl-Cayron, Philipp Schredl, Alexander D Bungert, Klaus Emmanuel, Dino Bekric, Jaroslav Presl, Andreas Pascher, Daniel Neureiter, Tarkan Jäger Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive disease in which cytoreductive surgery…
Read MoreLocalized Epithelioid Peritoneal Mesothelioma: A Rare Mimicker of Gynecological Malignancy
Cureus 2026 July 8 [Link] Francisco Carvalho, Daniela Pereira, Teresa Margarida Cunha Abstract Localized epithelioid peritoneal mesothelioma (LEPM) is a rare variant of peritoneal mesothelioma that presents as a solitary, circumscribed mass rather than with the diffuse serosal spread that characterizes the far more common diffuse form. Because it may arise in the pelvis and…
Read MoreInsights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines
Thoracic Cancer 2026 August [Link] Yani Wu, Fang Cao, Jiayin Dai, Zhenli Yang, Yanli Zhu, Dongmei Lin, Xiaocui Bian, Yuqin Liu Abstract Background: Pleural mesothelioma (PM) is an aggressive cancer with limited therapeutic options and poor prognosis, necessitating comprehensive model systems for mechanistic studies and drug discovery. Methods: Tumor cells were isolated from malignant pleural…
Read MoreBAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
Thoracic Cancer 2026 July [Link] Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki Abstract Introduction: Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1-associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated…
Read MoreImpact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study
In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Shohei Shimajiri, Fumihiro Tanaka Abstract Background/aim: While CD73 and CD155 are implicated in immune evasion and tumor progression,…
Read MoreAmivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
Journal of Thoracic Oncology 2026 June 20 [Link] Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Rohini Mopuri, Jennifer Ayers-Ringler, Lin Yang, Kim P Lauer, Katherine E R Smith, Yan W Asmann, Anja Roden, Farhad Kosari, Aaron S Mansfield Abstract Introduction: Diffuse pleural mesothelioma (DPM) is a lethal malignancy with no approved therapies directly targeting…
Read MoreIncreased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreClinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings
Journal of Clinical Pathology 2026 June 18 [Link] Dina Moustafa Thabit, Dalia M Thabet Abstract Aims: Distinguishing epithelioid malignant mesothelioma (EMM) from poorly differentiated lung adenocarcinoma (PD-LUAD) remains challenging, particularly when 21.7% of PD-LUADs lack lineage-specific markers (thyroid transcription factor-1 (TTF-1)/Napsin A), creating a diagnostic blind spot. While GATA-binding protein 3 (GATA3) is established in…
Read More
Skip to content